News | September 22, 2009

Robotic Stereotactic Radiotherapy Safe Alternative to Fractionated Radiotherapy

September 22, 2009 - Robotic stereotactic radiotherapy appeared to be a safe and obviously superior alternative to conventionally fractionated radiotherapy in a small cohort of patients with stage I non-small cell lung cancer (NSCLC), according to a study published in the October issue of Clinical Oncology.

In the study, researchers set out to determine the effectiveness of robotic stereotactic radiotherapy with image guidance and real-time respiratory tracking against early stage peripheral lung cancer.

All patients with stage I non-small cell lung cancer (NSCLC) were treated using CyberKnife. All patients had co-morbid conditions that precluded lobectomy. The clinical target volume (CTV) included the gross tumour volume (GTV) and a 6 mm margin in all directions to account for microscopic extension. The planning target volume (PTV) equalled CTVD + 2 mm in all directions for uncertainty. Tumor motion was tracked using a combination of Synchrony and Xsight Spine tracking methods with the aid of a single gold marker implanted in the center of the tumor, or using the newer Xsight Lung method without markers for selected tumors. A 60-67.5 Gy dose was prescribed to the 60-80 percent isodose line (median 65 percent) and given in three to five fractions. Patients were followed every 3 months for a median of 27.5 months (range 24-53 months).

Of the 67 patients with NSCLC stage IA or IB treated between January 2004 and December 2008, investigators reported the results of a cohort of 31 with peripheral stage I tumors of 0.6-71 cm3 volume treated between January 2004 and December 2007 with total doses between 60 and 67.5 Gy in three to five fractions. The median Dmax was 88.2 Gy and the median V95 of the PTV was 99.6 percent or 27.9 cm3. No grade 3 or above toxicity was encountered. Four cases of radiation pneumonitis and one case of oesophagitis were observed. In those patients whose pre- and post-treatment results were available, no change in pulmonary function tests was observed. Actuarial local control was 93.2 percent for 1 year and 85.8 percent for up to 4.5 years. One-year overall survival was 93.6 percent and 83.5 percent for up to 4.5 years, as projected by Kaplan-Meier analyses.

The researchers concluded that in this small cohort of patients with stage I peripheral NSCLC, robotic stereotactic radiotherapy seems to be a safe and obviously superior alternative to conventionally fractionated radiotherapy, with results that may be approaching those obtained with lobectomy without the associated morbidity.

Reference: Brown, W.T., Wu, X., Fayad, F., Fowler, J.F., García, S., Monterroso, M.I., de la Zerda, A., Schwade, J.G. Application of Robotic Stereotactic Radiotherapy to Peripheral Stage I Non-Small Cell Lung Cancer With Curative Intent. Clin Oncol. 2009 Oct 1;21(8):623-631.

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...